Loading clinical trials...

Natriuretic Effect of Amiloride in Relation to the Alpha Adducin Gene (ADD-AMI) RS4961 Variant | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Natriuretic Effect of Amiloride in Relation to the Alpha Adducin Gene (ADD-AMI) RS4961 Variant

Natriruetic Effect of Amiloride in Relation to the Alpha Adducin Gene (ADD-AMI) RS4961 Variant

NCT06416735•Ospedale San Raffaele

View on ClinicalTrials.gov

Summary

The study is a non-pharmacological interventional, single-center, national, non-randomised, comparative and open label.

Detailed Description

The study is carried out to evaluate primarily the difference in the activity of the renal transporter ENaC (through dosage of sodium) through its inhibition with a single dose of Amiloride in hypertensive patients characterized by the polymorphism of alpha Adducin rs496. It's also aimed to see the difference in potassium and the change in systolic and diastolic blood pressure after amiloride administration

Eligibility

Age

18 - 60 years

Sex

MALE

Healthy Volunteers

Inclusion Criteria

•male patients aged 18-60 years;
•naïve hypertensive patients: newly diagnosed, never previously treated for hypertension;
•BMI\<30 Kg/m2,
•documented first degree essential arterial hypertension (mean of the last 3 consecutive systolic BP measurements must be \>=140 mmHg or diastolic BP \>=90 mmHg;
•signature of the informed consent for participation in the study
•patient who has already undergone genomic DNA sampling (accompanied by relative consent) and genotyped for the ADD1 rs4961 variant (GG, GT or TT).

Exclusion Criteria

•known causes of secondary hypertension;
•severe or malignant hypertension; history of renal artery disease;
•significant renal disease (creatinine clearance less than 60 ml/min);
•hyperkalemia (Kpl \> 6mEq/l) at enrollment visit;
•hypercalcaemia (Ca pl \> 2.6 mmol/l) at enrollment visit;
•symptomatic hyperuricemia (\> 7.5 mg/dl);
•liver disease (transaminases greater than 3 times the normal value);
•cardiac pathologies (myocardial infarction, atrial fibrillation, etc.);
•diabetes (fasting blood sugar \>125mg/dl);
•in therapy with statins, NSAIDs, systemic steroids;
+2 more criteria

Locations (1)

San Raffaele Hospital

Milan, Lombardy, Italy

Key Dates

Start Date

September 28, 2018

Primary Completion Date

July 20, 2020

Completion Date

July 20, 2020

Last Updated

May 16, 2024

Enrollment

ACTUAL participants

Conditions

Hypertension EssentialSalt ExcessGenetic Hypertension

Interventions

Amiloride

DRUG

Genetic of Response to Acute Saline Load Test in Hypertension (Naload)

NCT04625569

Hypertension,EssentialSalt; Excess+2 more

View study

COMPLETED

Impact of a Family History of Hypertension and Physical Activity on Left Ventricular Mass

NCT05334355

Genetic PredispositionGenetic Hypertension

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 16, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions